Melphalan and other anticancer modalities up-regulate B7-1 gene expression in tumor cells

Journal of Immunology

Volumn 164, Issue 12, 2000, Pages 6230-6236

  Sojka, Dorothy K ^a   Donepudi, Manjula ^a   Bluestone, Jeffrey A ^b   Mokyr, Margalit B ^a  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^b UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B7 ANTIGEN; CD86 ANTIGEN; MELPHALAN; MESSENGER RNA; MITOMYCIN C;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN EXPRESSION; ANTINEOPLASTIC ACTIVITY; ARTICLE; DRUG EFFECT; FLOW CYTOMETRY; GAMMA IRRADIATION; GENE EXPRESSION REGULATION; IMMUNOPOTENTIATION; MOUSE; NONHUMAN; PLASMACYTOMA; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

EID: 0034660469     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.164.12.6230     Document Type: Article

References (53)

1. Hengst, J. C. D., M. B. Mokyr, and S. Dray. 1981. Cooperation between cyclophosphamide tumoricidal activity and host antitumor immunity in the cure of mice bearing large MOPC-315 tumors. Cancer Res. 41:2163
2. Ben-Efraim, S., R. C. Bocian, M. B. Mokyr, and S. Dray. 1983. Increase in the effectiveness of melphalan therapy with progression of MOPC-315 plasmacytoma tumor growth. Cancer Immunol. Immunother. 15:101.
3. Morikawa, K., M. Hosokawa, J. Hamada, M. Sugawara, and H. Kobayashi. 1985. Host-mediated therapeutic effects produced by appropriately timed administration of bleomycin on a rat fibrosarcoma. Cancer Res. 45:1502.
4. Berd, D., H. C. Maguire, and M. J. Mastrangelo. 1985. Induction of cell-mediated immunity to autologous melanoma cells and regression of metastases after treatment with melanoma cell vaccine preceded by cyclophosphamide. Cancer Res. 46:2572.
5. Sahasrabudhe, D. M., J. B. deKernion, J. E. Pontes, D. M. Ryan, R. W. O'Donnell, D. M. Marquis, G. S. Mudholkar, and C. S. McCune. 1986. Specific immunotherapy with suppressor function inhibition for metastatic renal cell carcinoma. J. Biol. Response Modif. 5:581.
6. Reissmann, T., R. Voegeli, J. Pohl, and P. Hilgard. 1989. Augmentation of host antitumor immunity by low-doses of cyclophosphamide and mafosfamide in two animal tumor models. Cancer Immunol Immunother. 28:179.
7. Nagarkatti, M., D. M. Toney, and P. S. Nagarkatti. 1989. Immunomodulation by various nitrosoureas and its effect on the survival of the murine host bearing a syngeneic tumor. Cancer Res. 49:6587.
8. + suppressor T-cells. Cancer Res. 49:1649.
9. + T cells to cause regression of an advanced lymphoma. Immunology 71:90.
10. Berd, D., H. C. Maguire, P. McCue, and M. J. Mastrangelo. 1990. Treatment of metastatic melanoma with an autologous tumor-cell vaccine: clinical and immunologic results in 64 patients. J. Clin. Oncol. 8:1858.
11. Berd, D., G. Murphy, H. C. Maguire, and M. J. Mastrangelo. 1991. Immunization with haptenized autologous tumor cells induces inflammation of human melanoma metastases. Cancer Res. 51:2731.
12. Weiskirch, L. M., Y. bar-Dagan, and M. B. Mokyr. 1994. Transforming growth factor-β-mediated down-regulation of antitumor cytotoxicity of spleen cells from MOPC-315 tumor bearing mice engaged in tumor eradication following low-dose melphalan-therapy. Cancer Immunol. Immunother. 38:215.
13. Gorelik, L., A. Prokhorova, and M. B. Mokyr. 1994. Low-dose melphalan-induced shift in the production of a Th2-type cytokine to a Th1-type cytokine in mice bearing a large MOPC-315 tumor. Cancer Immunol. Immunother. 39:117.
14. Lattime, E. C., M. J. Mastrangelo, O. Bagasra, W. Li, and D, Berd. 1995. Expression of cytokine mRNA in human melanoma tissue. Cancer Immunol. Immunother. 41:151.
15. Yuan, L., Y. Kuramitsu, Y. Li, M. Kobayashi, and M. Hosokawa. 1995. Restoration of interleukin-2 production in tumor-bearing rats through reduction of tumor-derived transforming growth factor β by treatment with bleomycin. Cancer Immunol. Immunother. 41:355.
16. Gorelik, L., M. Rubin, A. Prokhorova, and M. B. Mokyr. 1995. Importance of TNF production for the curative effectiveness of low-dose melphalan therapy for mice bearing a large MOPC-315 tumor. J. Immunol. 154:3941.
17. Gorelik, L., and M. B. Mokyr. 1995. Low-dose melphalan-induced up-regulation of type-1 cytokine expression in the s.c. tumor nodule of MOPC-315 tumor bearers and the role of interferon-γ in the therapeutic outcome. Cancer Immunol. Immunother. 41:363.
18. Mokyr, M. B., T. V. Kalinichenko, and L. Gorelik. 1997. Potentiation of antitumor CTL response by GM-CSF involves a B7-dependent mechanism. Cell. Immunol. 178:152.
19. Mokyr, M. B., T. V. Kalinichenko, L. Gorelik, and J. A. Bluestone. 1998. Importance of the B7-2 molecule for low dose melphalan-induced acquisition of tumor-eradicating immunity by mice bearing a large MOPC-315 tumor. J. Immunol. 160:1866.
20. + T-cells in the curative effectiveness of a low dose of melphalan for mice bearing a large MOPC-315 tumor. Cancer Res. 49:4597.
21. 8 T-cells in eradication of a large subcutaneous MOPC-315 tumor following low-dose melphalan therapy. Cancer Res. 50:7641.
22. Chen, L., P. S. Linsley, and K. E. Hellstrom. 1993. Costimulation of T cells for tumor immunity. Immunol. Today 14:483.
23. Allison, J. P., A. A. Hurwitz, and D. R. Leach. 1995. Manipulation of costimulatory signals to enhance T-cell responses. Curr. Opin. Immunol 7:682.
24. Schwartz, R. H. 1992. Costimulation of T lymphocytes: the role of CD28, CTLA-4, and B7/BB1 in interleukin-2 production and immunotherapy. Cell 71:1065.
25. Huang, A. Y., A. T. Brace, D. M. Pardoll, and H. I. Levitsky. 1996. Does B7-1 expression confer antigen-presenting cell capacity to tumors in vivo? J. Exp. Med. 183:769.
26. La Motte, R. N., A. H. Sharpe, J. A. Bluestone, and M. B. Mokyr. 1998. Importance of B7-1-expressing host antigen-presenting cells for the eradication of B7-2 transfected P815 tumor cells. J. Immunol. 161:6552.
27. + T cell-dependent mechanism. J. Immunol. 162:4817.
28. La Motte, R. N., M. A. Rubin, E. Barr, J. M. Leiden, J. A. Bluestone, and M. B. Mokyr. 1996. Therapeutic effectiveness of the immunity elicited by P815 tumor cells engineered to express the B7-2 costimulatory molecule. Cancer Immunol. Immunother. 42:161.
29. Bocian, R. C., S. Dray, S. Ben-Efraim, and M. B. Mokyr. 1985. Melphalan-induced enhancement of tumor cell immunostimulatory capacity as a mechanism for the appearance of potent antitumor immunity in the spleen of mice bearing a large metastatic MOPC-315 tumor. Cancer Immunol. Immunother. 20:61.
30. Lenschow, D. J., S. C. Ho, H. Sattar, L. Rhee, G Gray, N. Nabavi, K. C. Herold, and J. A. Bluestone. 1995. Differential effects of anti-B7-1 and anti-B7-2 monoclonal antibody treatment on the development of diabetes in the nonobese diabetic mouse. J. Exp. Med. 181:1145.
31. Hathcock, K. S., G. Laszlo, C. Pucillo, P. Linsley, and R. J. Hodes. 1994. Comparative analysis of B7-1 and B7-2 costimulatory ligands: expression and function. J. Exp. Med. 180:631.
32. Lenschow, D. J., G. H.-T. Su, L. A. Zuckerman, N. Nabavi, C. L. Jellis, G. S. Gray, J. Miller, and J. A. Bluestone. 1993. Expression and functional significance of an additional ligand for CTLA-4. Proc. Natl. Acad. Sci. USA 90:11054.
33. + T cells by B7-transfected melanoma cells. Science 259:368.
34. Seo, A., F. Ishikawa, H. Nakano, H. Nakazaki, K. Kobayashi, and T. Kakiuchi, 1999. Enhancement of B7-1 (CD80) expression on B-lymphoma cells by irradiation. Immunology 96:642.
35. Kuchroo, V. K., M. P. Das, J. A. Brown, A. M. Ranger, S. S. Zamvil, R. A. Sobel, H. L. Weiner, N. Nabavi, and L. H. Glimcher. 1995. B7-1 and B7-2 costimulatory molecules activate differentially the Th1/Th2 development pathways: application to autoimmune disease therapy. Cell 80:707.
36. Freeman, G. J., V. A. Boussiotis, A. Anumanthan, G. M. Bernstein, X.-Y. Ke, P. D. Rennert, G. S. Gray, J. G. Gribben, and L. N. Nadler. 1995. B7-1 and B7-2 do not deliver identical costimulatory signals, since B7-2 but not B7-1 preferentially costimulate the initial production of IL-4. Immunity 2:523.
37. Tsuyuki, S., J. Tsuyuki, K. Einsle, M. Kopf, and A. Coyle. 1997. Costimulation through B7-2 (CD86) is required for the induction of a lung mucosal T helper cell 2 (TH2) immune response and altered airway responsiveness. J. Exp. Med. 185: 1671.
38. Greenfield, S. C., E. Howard, G. J. Freeman, and V. K. Kuchroo. 1999. B7-2 expressed on EL4 lymphoma suppresses antitumor immunity by an interleukin 4-dependent mechanism. J. Exp. Med. 189:919.
39. Girvin, A. M., M. C. Dal Canto, L. Rhee, B. Salomon, A. Sharpe, J. A. Bluestone, and S. D. Miller. 2000. A critical role for B7/CD28 costimulation in experimental autoimmune encephalomyelitis: a comparative study using costimulatory molecule-deficient mice and monoclonal antibody blockade. J. Immunol. 164:136.
40. + lymphocytes in the P815 tumor system in vitro. J. Immunol. 156:465.
41. Brach, M. A., R. Hass, M. L. Sherman, H. Gunji, R. Weichselbaum, and D. Kufe, 1991. Ionizing radiation induces expression and binding activity of the nuclear factor κB. J. Clin. Invest. 88:691.
42. Brach, M. A., H. J. Grass, T. Kaisho, Y. Asano, T. Hirano, and F. Hermann. 1993. Ionizing radiation induces expression of interleukin 6 by human fibroblasts involving activation of nuclear factor-κB. J. Biol. Chem. 268:8466.
43. Lee, S. J., A. Dimitchev, M. F. Lavin, A. Dritschilo, and M. Jung. 1998. A novel ionizing radiation-induced pathway that activates the transcription factor NF-κB. Oncogene 17:1821.
44. Baldassarre, F., M. Mallardo, E. Mezza, G. Scala, and I. Quinto. 1995. Regulation of NF-κB through nuclear processing of p105 (NF-κB1) in Epstein-Barr virus-immortalized B cell lines. J. Biol. Chem. 270:31244.
45. Yao, K. S., A. Hageboutros, P. Ford, and P. O'Dwyer. 1997. Involvement of activator protein-1 and nuclear factor-κB transcription factors in the control of DT-diaphorase expression induced by mitomycin C treatment. J. Mol. Pharmacol. 51:422.
46. Zhao, J., G. J. Freeman, G. S. Gray, L. M. Nadler, and L. H. Glimcher. 1996. A cell type-specific enhancer in the human B7.1 gene regulated by NF-κB. J. Exp. Med. 183:777.
47. Zhang, H., D. Haasch, K. B. Idler, and G. F. Okasinski. 1996. Isolation and promoter mapping of the gene encoding murine co-stimulatory factor B7-1. Gene 183:1.
48. Zhang, H., D. Haasch, B. Patterson, B. Dickinson, L. Kifle, D. G. Fray, and G. F. Okasinski. 1999. A novel stimulus, oncogene, induces expression of CD80 (B7-1) gene. Tumor Biol. 20:193.
49. Antonia, S. J., C. Finley, and T. Munoz-Antonia. 1996. Cloning and partial characterization of the mouse B7-1 promoter. Immunogenetics 43:234.
50. Sherman, M. L., R. Datta, D. E. Hallahan, R. R. Weichselbaum, and D. W. Kufe. 1991. Regulation of tumor necrosis factor gene expression by ionizing radiation in human myeloid leukemia cells and peripheral blood monocytes. J. Clin. Invest. 87:1794.
51. Hong, J. H., C. S. Chiang, I. L. Campbell, J. R. Sun, H. R. Withers, and W. H. McBride. 1995. Induction of acute phase gene expression by brain irradiation. Int. J. Radial. Oncol. Biol. Phys. 33:619.
52. Barcellos-Hoff, M. 1993. Irradiation-induced transforming growth factor β and subsequent extracellular matrix reorganization in murine mammary gland. Cancer Res. 53:3880.
53. Hallahan, D., E. T. Clark, J. Kuchibhotla, B. L. Gewertz, and T. Collins. 1995. E-selectin gene induction by ionizing radiation is independent of cytokine induction. Biochem. Biophys. Res. Commun. 217:784.